Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 10
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
7/30/2007
 
First Published:
3/1/2001
1.
Phase III Randomized Study of Nolatrexed Dihydrochloride Versus Doxorubicin in Patients With Unresectable or Recurrent Hepatocellular Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
Pharmaceutical / Industry
ZARIX-ZX101-301
AG-337-301, NCT00012324
Last Modified:
9/1/1995
2.
Phase II Study of Continuous-Infusion AG-337 (a Thymidylate Synthase Inhibitor) for Adenocarcinoma of the Pancreas (Summary Last Modified 09/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
over 18
Pharmaceutical / Industry
AG-337-006
NCI-V95-0632
Last Modified:
8/1/1995
3.
Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Primary Hepatocellular Carcinoma (Summary Last Modified 08/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
AG-337-008
NCI-V95-0633
Last Modified:
6/1/1997
4.
Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Prostate Cancer (Summary Last Modified 06/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
AG-337-007
NCI-V95-0634
Last Modified:
1/1/1996
5.
Phase II Study of AG337 by 5-Day Continuous Infusion in Adenocarcinoma of the Colon (Summary Last Modified 01/96)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
AG-337-009
NCI-V95-0635
Last Modified:
8/1/1995
6.
Phase II Study of AG-337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 08/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
AG-337-004
NCI-V95-0636
Last Modified:
6/1/1997
7.
Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Stage IIIB/IV Nonsmall Cell Lung Cancer (Summary Last Modified 06/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
AG-337-005
NCI-V95-0637
Last Modified:
2/1/1998
8.
Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) Administered as a 5-Day Continuous Infusion for Locally Advanced or Metastatic Hepatocellular Carcinoma (Summary Last Modified 02/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
AG-337-015
NCI-V96-0946
Last Modified:
2/1/1998
9.
Phase II Randomized Study of AG337 (a Thymidylate Synthase Inhibitor) vs MTX in Patients Who Have Failed First-Line Chemotherapy for Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 02/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
AG-337-016
NCI-V96-0949
Last Modified:
2/1/1998
10.
Phase I Study of Continuous-Infusion AG337, a Thymidylate Synthase Inhibitor, plus CDDP for Advanced Solid Tumors (Summary Last Modified 02/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
AG-337-013
NCI-V96-0874
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute